Xofluza® (baloxavir marboxil) – Expanded indications
August 11, 2022 - Genentech announced the FDA approval of Xofluza (baloxavir marboxil), for the treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours and who are otherwise healthy adults and pediatric patients 5 years of age and older.
Top